Inhibitors of heat shock protein 90 (HSP90), a molecular chaperone controlling the RIPK3 and MLKL stability and function, such as kongensin A, 17AAG, IPI-504 and Alvespimycin (17-D MAG), both in clinical trials in cancer patients, may indirectly impair necroptosis [146]. This evidence concerns the gene MLKL and cancer.